One of the 3 geniuses faosto, mag, igo deleted the cldn post where they admit they loved cldn. Lmfao hope they fair better in their analysis of achn!
Thats fine if you want that to be your perspective but the rest of the market does not agree w you, they clearly know that sovaldi is the mvp in either combo you refer to. There is only one top notch nuc in the marketplace - sovaldi. There are 3-5 top notch 5As, and hopefully the P2 data from 3102 will prove its one of 3-5 but it will still be just one of 3-5, and there will still be only one sovaldi and the nuc will still be the mvp. That is achns problem from my point of view and why the stock has trended from 16-10 while at same time IBB is up huge. But again we should probably wait for the P2 data to come out and then reassess. The last time achn released major P2 data w its protease the stock tanked from 10-12 to 2 so there are no guarantees obviously. Good luck!
Obviously achn only achieved "at or near" 100% w a competitor compound. Not sure why you would get overly excited about that? Before you make any grand statements about achn and the hep C market place you probably should let them produce data from an in depth phase 2 trial with more than 12 patients for 6 week treatment. Any scientist knows this. And the market lately would seem to agree for whatever thats worth
Pretty pls show me a post that i was short below 7, because i wasnt. Just because you dont believe in a co doesnt mean you go short at any price
Why? Where have i been wrong. Im certainly not wrong on insider sales. Thats for sure. This company has nothing and you know it. Just read your recent posts on achn , you agree. So if i am full of it so are you. Cheers and good luck!
I shorted during after hours after that PR, and more at 16, made a killing. Hey i like this post of yours:
a.biopharm • Apr 21, 2015 1:06 PM Flag
0users liked this postsusers disliked this posts2Reply
"3102 is the most potent NS5A in development by far and was the primary reason such extreme viral reduction took place"...
binary_departure101 • Apr 21, 2015 1:11 PM Flag
1users liked this postsusers disliked this posts0Reply
but who needs it? where does it fit? GILD sales are crushing the competition, so not much incentive for them to take it..no?
I fully agree
And why would RA be involved in talks? Unless you are insinuating RA really runs this company? Now you might be onto something......and they sold over 100 mill $ last year......
Yep they must be in perpetual talks, managers havent bought in over a year and half and since it was under 3. Those are some negotiations
Conversely they were doing the type of same thing from 2.5 to 16......all so RA, ceo, cfo, chairman could DUMP millions of shares. Any buys recently by management at these bargain basement prices?? No? Lol
Guys read the scientific literature......or twitter.....big pharma is actively moving on from hep C to hep B. Check out tkmr, arwr, etc etc.....
Can you claim "best" based on 12 patients at 6 weeks? (Also any non responders in those 12? ) The market doesnt seem to agree. I wonder why?
Then why on earth hasnt it happened yet? Maybe achn should hurry up and run the 5a w more patients? How many patients in their last comprehensive trial?
Hopefully achn starts some real trials soon with the 5a so gild can compare it to the 4-5 other 5a s out there, the clock is ticking. Bmy is probably shopping their 5a around after having done very in depth trials on it.....